Overview

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease (AD).

Phase:

Phase 2

Details

Lead Sponsor:

Avid Radiopharmaceuticals

Treatments:

Fluorodeoxyglucose F18